Inhibitor | Progesterone | PGE1 | l-Sirenin | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Conc., µM | pEC50 | Emax, % | n | pEC50 | Emax, % | n | pEC50 | Emax, % | n | |
MBF | 1 | 8.71 ± 0.29 | 90 | 3 | 8.16 ± 0.08 | 87 | 3 | 5.71 ± 0.01 | 87 | 2 |
10 | 8.14 ± 0.20 | 69 | 4 | 8.53 ± 0.37 | 53 | 4 | 5.57 ± 0.41 | 58 | 4 | |
30 | 8.31 ± 0.42 | 23 | 4 | 8.23 ± 0.51 | 41 | 3 | 5.37 ± 0.51 | 20 | 4 | |
100 | 8.26 ± 0.24 | 16 | 3 | — | <10 | 5 | — | <10 | 3 | |
ML218 | 1 | 8.12 ± 0.13 | 83 | 3 | 8.20 ± 0.10 | 73 | 3 | ND | ||
10 | 7.77 ± 0.35 | 42 | 3 | 8.01 ± 0.05 | 64 | 3 | 5.61 ± 0.45 | 38 | 2 | |
30 | — | <10 | 3 | 7.86 ± 0.04 | 15 | 3 | — | 4 | 2 | |
100 | — | <10 | 3 | — | <10 | 2 | — | 2 | 2 | |
MPA | 10 | 7.69 ± 0.40 | 106 | 3 | 7.83 ± 0.43 | 111 | 3 | 5.56 ± 0.15 | 108 | 3 |
30 | 7.51 ± 0.38 | 99 | 3 | 7.34 ± 0.15 | 105 | 3 | 5.24 ± 0.58 | 100a | 3 | |
100 | 6.64 ± 0.07 | 100a | 3 | 6.96 ± 0.03 | 100a | 3 | 4.71 ± 0.21 | 100a | 3 | |
LNG | 10 | 7.58 ± 0.16 | 110 | 8 | 7.78 ± 0.30 | 96 | 4 | 5.16 ± 0.08 | 95 | 4 |
30 | 7.06 ± 0.26 | 100a | 4 | 7.48 ± 0.18 | 106 | 4 | 4.83 ± 0.16 | 102 | 4 | |
100 | 6.64 ± 0.06 | 100a | 4 | 7.29 ± 0.22 | 117 | 4 | 4.52 ± 0.03 | 100a | 3 | |
ALDO | 10 | 7.44 ± 0.14 | 114 | 4 | 7.88 ± 0.22 | 107 | 4 | 5.28 ± 0.28 | 104 | 4 |
30 | 7.09 ± 0.36 | 106 | 4 | 7.82 ± 0.31 | 99 | 4 | 5.10 ± 0.24 | 109 | 4 | |
100 | 6.59 ± 0.16 | 100a | 4 | 7.44 ± 0.31 | 100a | 4 | 4.51 ± 0.21 | 100a | 4 |
EC50 values are expressed as the mean ±SD, and Emax values are the percent of a saturating concentration of PROG (3 µM). The number of independent experiments is indicated by n. EC50, Emax, and n values for PROG, PGE1, and l-sirenin in the absence of inhibitor are in Table 2. Fitted parameters were not calculated for conditions producing Emax < 10.
↵a Constrained value due to rightward shift of dose response.